litlas
Log inCreate account

Shitij Kapur

Active 1992–2024

182
Papers
47,764
Citations
115
h-index
179
i10-index

Citations

Citations per year for Shitij Kapur1944: 1 citations1973: 3 citations1974: 1 citations1979: 1 citations1983: 1 citations1993: 3 citations1994: 25 citations1995: 59 citations1996: 142 citations1997: 170 citations1998: 257 citations1999: 263 citations2000: 292 citations2001: 299 citations2002: 349 citations2003: 351 citations2004: 339 citations2005: 413 citations2006: 414 citations2007: 399 citations2008: 410 citations2009: 374 citations2010: 507 citations2011: 446 citations2012: 498 citations2013: 551 citations2014: 573 citations2015: 622 citations2016: 599 citations2017: 519 citations2018: 399 citations2019: 1,387 citations2020: 1,203 citations2021: 961 citations2022: 725 citations2023: 404 citations2024: 744 citations2025: 283 citations2026: 11 citations1945–1972: no citations, so these years are not shown1975–1978: no citations, so these years are not shown1980–1982: no citations, so these years are not shown1984–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,465 citing papers, 25.6% of this breakdownUnited Kingdom: 2,223 citing papers, 12.7% of this breakdownCanada: 1,372 citing papers, 7.9% of this breakdownGermany: 1,141 citing papers, 6.5% of this breakdownAustralia: 696 citing papers, 4% of this breakdownItaly: 688 citing papers, 3.9% of this breakdownNetherlands: 665 citing papers, 3.8% of this breakdownChina: 652 citing papers, 3.7% of this breakdownFrance: 485 citing papers, 2.8% of this breakdownSwitzerland: 464 citing papers, 2.7% of this breakdownSpain: 416 citing papers, 2.4% of this breakdownJapan: 405 citing papers, 2.3% of this breakdown
0%25.6%Other 21.7%

Institutions

Fields

  • Neuroscience38.1%
  • Medicine37.1%
  • Psychology10.5%
  • Biochemistry, Genetics and Molecular Biology8.6%
  • Arts and Humanities1%
  • Computer Science0.8%
  • Other3.9%

Topics

  • Schizophrenia research and treatment8.6%
  • Functional Brain Connectivity Studies5.3%
  • Neurotransmitter Receptor Influence on Behavior4.8%
  • Neural and Behavioral Psychology Studies3.7%
  • Memory and Neural Mechanisms3.4%
  • Neuroscience and Neuropharmacology Research3.4%
  • Other70.8%

Coauthors

All papers

Open in search
  1. The Dopamine Hypothesis of Schizophrenia: Version III-The Final Common Pathway

    Authors: Oliver Howes, Shitij Kapur - Schizophrenia Bulletin 2009 cited by 2,670

  2. Psychosis as a State of Aberrant Salience: A Framework Linking Biology, Phenomenology, and Pharmacology in Schizophrenia

    Authors: Shitij Kapur - American Journal of Psychiatry 2002 cited by 2,792

  3. Schizophrenia

    Authors: Jim van Os, Shitij Kapur - The Lancet 2009 cited by 1,963

  4. Grand challenges in global mental health

    Authors: Pamela Y. Collins, Vikram Patel, Sarah S. Joestl, Dana March, Thomas R. Insel, Abdallah S. Daar, Isabel A. Bordin, E. Jane Costello, Maureen S. Durkin, Christopher Fairburn, Roger I. Glass, Wayne Hall, Yueqin Huang, Steven E. Hyman, Kay Redfield Jamison, Sylvia Kaaya, Shitij Kapur, Arthur Kleinman, Adesola Ogunniyi, Angel A. Otero-Ojeda, Mu‐ming Poo, Vijayalakshmi Ravindranath, Barbara J. Sahakian, Shekhar Saxena, Peter Singer, Dan J. Stein, Warwick P. Anderson, Muhammad A. Dhansay, Wendy Ewart, Anthony G. Phillips, Susan B. Shurin, Mark Walport - Nature 2011 cited by 2,083

  5. The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment

    Authors: Oliver Howes, Joseph Kambeitz, Euitae Kim, Daniel Ståhl, Mark Slifstein, Anissa Abi‐Dargham, Shitij Kapur - Archives of General Psychiatry 2012 cited by 959

  6. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?

    Authors: Shitij Kapur, Anthony G. Phillips, Thomas R. Insel - Molecular Psychiatry 2012 cited by 1,005

  7. Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology

    Authors: Sagnik Bhattacharyya, Paul D. Morrison, Paolo Fusar‐Poli, Rocı́o Martı́n-Santos, Stefan Borgwardt, Toby Winton‐Brown, Chiara Nosarti, Colin M O' Carroll, Marc L. Seal, Paul Allen, Mitul A. Mehta, James Stone, Nigel Tunstall, Vincent Giampietro, Shitij Kapur, Robin Murray, Antônio Waldo Zuardi, José Alexandre S. Crippa, Zerrin Atakan, Philip McGuire - Neuropsychopharmacology 2009 cited by 678

  8. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment

    Authors: Amir Englund, Paul D. Morrison, Judith Nottage, Dominic Hague, Fergus Kane, Stefania Bonaccorso, James Stone, Avi Reichenberg, Rudolf Brenneisen, David Holt, Amanda Feilding, Lucy Walker, Robin Murray, Shitij Kapur - Journal of Psychopharmacology 2012 cited by 462

  9. Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia

    Authors: Shitij Kapur, Robert B. Zipursky, Corey Jones, Gary Remington, Sylvain Houle - American Journal of Psychiatry 2000 cited by 1,083

  10. CSACI guidelines for the ethical, evidence-based and patient-oriented clinical practice of oral immunotherapy in IgE-mediated food allergy

    Authors: Philippe Bégin, Edmond S. Chan, H. Kim, Monika Wagner, Marjo Cellier, Caroline Favron‐Godbout, Elissa M. Abrams, Moshe Ben‐Shoshan, Scott B. Cameron, Stuart Carr, David Fischer, A. Haynes, Shitij Kapur, Marie-Noël Primeau, Julia Upton, Timothy K. Vander Leek, Mireille Goetghebeur - Allergy Asthma and Clinical Immunology 2020 cited by 183

  11. Antipsychotic Treatment Resistance in Schizophrenia Associated with Elevated Glutamate Levels but Normal Dopamine Function

    Authors: Arsime Demjaha, Alice Egerton, Robin Murray, Shitij Kapur, Oliver Howes, James Stone, Philip McGuire - Biological Psychiatry 2013 cited by 344

  12. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study

    Authors: René S. Kahn, Inge Winter van Rossum, Stefan Leucht, Philip McGuire, Shôn Lewis, Shon W Lewis, Celso Arango, Paola Dazzan, Richard Drake, Stephan Heres, Covadonga M. Díaz‐Caneja, Covadonga M Díaz-Caneja, Mark Weiser, Silvana Galderisi, Birte Glenthøj, Marinus J.C. Eijkemans, W. Wolfgang Fleischhacker, Shitij Kapur, Iris E. Sommer, René S. Kahn, Iris E. Sommer, Inge Winter-van Rossum, Metten Somers, Paula C Ywema, S. Kapur, Philip McGuire, Shitisj Kapur, Andreas Meyer‐Lindenberg, Shôn Lewis, Stefan Leucht, Celso Arango, Wolfgang Fleischhacker, Anne Lotte Meijering, Jocelyn Petter, Resy van de Brug, Joost Schotsman, Jildou Zwerver, Jos Peuskens, Jildou Zwerver, E Thys, Lucho G Hranov, Valentin Hranov, Jan Libiger, Richard M. Köhler, Pavel Mohr, Birte Glenthøj, Brian V. Broberg, Signe Wegmann Düring, Lone Baandrup, Stéphane Jamain, Lone Baandrup, Stephane Jamain, Ina Giegling, Dan Rujescu, M Heim, Michael Davidson, Mor Bar Heim, Paola Bucci, Armida Mucci, Janusz Rybakowski, Agnieszka Remlinger-Molenda, Ilan Gonen, Paull Radu, Marina Díaz‐Marsá, Alberto González Rodríguez, Tomás Palomo, Roberto Rodríguez–Jiménez, Tomas Palomo, Miquel Bernardo, Julio Bobes, Christina Vilares Oliveira, Gregor Berger, Claudia Wildt, Paola Dazzan, Roccio Perez-Iglesias, Richard Drake, Sarah Gregory, Danielle Wilson, Covadonga M. Díaz‐Caneja, Marinus J.C. Eijkemans, Covadonga M. Díaz‐Caneja, Marinus J.C. Eijkemans - The Lancet Psychiatry 2018 cited by 197

  13. Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study

    Authors: Sameer Jauhar, Mattia Veronese, Matthew M. Nour, Maria Rogdaki, Pamela Hathway, Federico Turkheimer, James Stone, Alice Egerton, Philip McGuire, Shitij Kapur, Oliver Howes - Molecular Psychiatry 2018 cited by 183

  14. CNVs conferring risk of autism or schizophrenia affect cognition in controls

    Authors: Hreinn Stefánsson, Andreas Meyer‐Lindenberg, Stacy Steinberg, Brynja B. Magnúsdóttir, Katrin Morgen, Sunna Arnarsdóttir, Gyða Björnsdóttir, G. Bragi Walters, Guðrún A. Jónsdóttir, Orla Doyle, Heike Tost, O. Grimm, Solveig Kristjansdottir, Heimir Snorrason, Solveig Davidsdottir, Lárus J. Gudmundsson, Guðbjörn F. Jónsson, Berglind Stefánsdóttir, Isafold Helgadottir, Magnús Haraldsson, Birna Jónsdóttir, Johan H. Thygesen, Adam J. Schwarz, Michael Didriksen, Tine B. Stensbøl, Michael Brammer, Shitij Kapur, Jónas G. Halldórsson, Stefán Hreiðarsson, Evald Sæmundsen, Engilbert Sigurðsson, Kari Stefansson - Nature 2013 cited by 735

  15. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation

    Authors: Oliver Howes, Francis Vergunst, Siobhan Gee, Philip McGuire, Shitij Kapur, David Taylor - The British Journal of Psychiatry 2012 cited by 354

  16. Dopamine Synthesis Capacity in Patients With Treatment-Resistant Schizophrenia

    Authors: Arsime Demjaha, Robin Murray, Philip McGuire, Shitij Kapur, Oliver Howes - American Journal of Psychiatry 2012 cited by 346

  17. Does Fast Dissociation From the Dopamine D2Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis

    Authors: Shitij Kapur, Philip Seeman - American Journal of Psychiatry 2001 cited by 1,129

  18. Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA)

    Authors: Alice Egerton, Anna Murphy, J Donocik, Adriana Anton, Gareth J. Barker, Tracy Collier, J.F.W. Deakin, Richard Drake, Emma Eliasson, Richard Emsley, Catherine J. Gregory, Kira Griffiths, Shitij Kapur, Laura Kassoumeri, Laura Knight, Emily Lambe, Stephen M. Lawrie, Jane Lees, Shôn Lewis, David J Lythgoe, Julian C. Matthews, Philip McGuire, Lily McNamee, Scott Semple, Alexander D. Shaw, Krish D. Singh, Charlotte Stockton-Powdrell, Peter S. Talbot, Mattia Veronese, Ernest H. Wagner, James Walters, S. R. Williams, James H. MacCabe, Oliver Howes - Schizophrenia Bulletin 2020 cited by 95

  19. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme

    Authors: Dragana Bugarski‐Kirola, Nakao Iwata, Snjezana Sameljak, Carol Reid, Thomas Blaettler, Laurie Millar, Tiago Reis Marques, George Garibaldi, Shitij Kapur - The Lancet Psychiatry 2016 cited by 96

  20. Dopaminergic Function in Cannabis Users and Its Relationship to Cannabis-Induced Psychotic Symptoms

    Authors: Michael Bloomfield, Celia J. A. Morgan, Alice Egerton, Shitij Kapur, H. Valerie Curran, Oliver Howes - Biological Psychiatry 2013 cited by 221

  21. The Effect of Paroxetine on 5-HT2A Receptors in Depression: An [18F]Setoperone PET Imaging Study

    Authors: Jeffrey H. Meyer, Shitij Kapur, Beata S. Eisfeld, Gregory M. Brown, Sylvain Houle, Jean DaSilva, Alan A. Wilson, Shahryar Rafi‐Tari, HS Mayberg, Sidney H. Kennedy - American Journal of Psychiatry 2001 cited by 233

  22. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors—implications for models of schizophrenia

    Authors: Shitij Kapur, Philip Seeman - Molecular Psychiatry 2002 cited by 462

  23. An Algorithm-Based Approach to First-Episode Schizophrenia

    Authors: Ofer Agid, Tamara Arenovich, Gautam Sajeev, Robert B. Zipursky, Shitij Kapur, George Foussias, Gary Remington - The Journal of Clinical Psychiatry 2011 cited by 223

  24. From dopamine to salience to psychosis—linking biology, pharmacology and phenomenology of psychosis

    Authors: Shitij Kapur, Romina Mizrahi, Ming Li - Schizophrenia Research 2005 cited by 509